Top-Rated StocksTop-RatedNASDAQ:UTHR United Therapeutics (UTHR) Stock Price, News & Analysis → Claim Your Complimentary Bitcoin Reward (From Crypto Swap Profits) (Ad) Free UTHR Stock Alerts $260.51 -1.89 (-0.72%) (As of 05:27 PM ET) Add Compare Share Share Today's Range$256.08▼$264.8550-Day Range$223.58▼$262.4052-Week Range$204.44▼$264.85Volume587,222 shsAverage Volume461,113 shsMarket Capitalization$11.56 billionP/E Ratio12.32Dividend YieldN/APrice Target$308.78 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get United Therapeutics alerts: Email Address United Therapeutics MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.90 Rating ScoreUpside/Downside18.5% Upside$308.78 Price TargetShort InterestHealthy9.96% of Float Sold ShortDividend StrengthN/ASustainability-2.00Upright™ Environmental ScoreNews Sentiment0.90Based on 35 Articles This WeekInsider TradingSelling Shares$33.57 M Sold Last QuarterProj. Earnings Growth4.90%From $23.88 to $25.05 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.77 out of 5 starsMedical Sector61st out of 908 stocksPharmaceutical Preparations Industry19th out of 424 stocks 3.5 Analyst's Opinion Consensus RatingUnited Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.90, and is based on 9 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageUnited Therapeutics has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 3.0 Short Interest Percentage of Shares Shorted9.96% of the float of United Therapeutics has been sold short.Short Interest Ratio / Days to CoverUnited Therapeutics has a short interest ratio ("days to cover") of 9.4.Change versus previous monthShort interest in United Therapeutics has recently decreased by 11.66%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldUnited Therapeutics does not currently pay a dividend.Dividend GrowthUnited Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreUnited Therapeutics has received a 71.80% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Antihypertensives (C02)" and "Cancer medication (L01)" products. See details.Environmental SustainabilityThe Environmental Impact score for United Therapeutics is -2.00. Previous Next 2.7 News and Social Media Coverage News SentimentUnited Therapeutics has a news sentiment score of 0.90. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.40 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 35 news articles for United Therapeutics this week, compared to 6 articles on an average week.Search InterestOnly 14 people have searched for UTHR on MarketBeat in the last 30 days. This is a decrease of -13% compared to the previous 30 days.MarketBeat FollowsOnly 6 people have added United Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, United Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $33,572,685.00 in company stock.Percentage Held by Insiders12.50% of the stock of United Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions94.08% of the stock of United Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.9 Earnings and Valuation Earnings GrowthEarnings for United Therapeutics are expected to grow by 4.90% in the coming year, from $23.88 to $25.05 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of United Therapeutics is 12.32, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 126.60.Price to Earnings Ratio vs. SectorThe P/E ratio of United Therapeutics is 12.32, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 120.87.Price to Book Value per Share RatioUnited Therapeutics has a P/B Ratio of 2.05. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Priority GoldBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentially cancel your money. You see Biden and the Fed have teamed up to create a controllable, traceable, programmable digital currency to replace the dollar...Get your free information kit NOW, before it's too late. About United Therapeutics Stock (NASDAQ:UTHR)United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.Read More UTHR Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart UTHR Stock News HeadlinesMay 4, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $929,124.00 in StockMay 2, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $847,260.00 in StockMay 6, 2024 | InvestorPlace (Ad)You need to know these two things about AI stocks ASAP…For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.April 30, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 3,600 Shares of StockApril 18, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $835,380.00 in StockApril 16, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Sells $847,512.00 in StockApril 13, 2024 | insidertrades.comMartine A. Rothblatt Sells 13,800 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockApril 10, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 5,060 Shares of StockMay 6, 2024 | InvestorPlace (Ad)You need to know these two things about AI stocks ASAP…For 40 years, he's been known as one of the world's most bullish investors. Forbes even referred to him a "perma bull"... But he just shocked the world by issuing a massive bear warning about AI stocks.April 8, 2024 | insidertrades.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 15,000 SharesApril 6, 2024 | insidertrades.comInsider Selling: United Therapeutics Co. (NASDAQ:UTHR) CEO Sells 15,000 Shares of StockMay 6, 2024 | investorplace.com3 Biotech Stocks to Double Your Money in the Next 24 MonthsMay 6, 2024 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Price Target Raised to $240.00May 6, 2024 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Stock Rating Reaffirmed by HC WainwrightMay 6, 2024 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) PT Raised to $400.00May 5, 2024 | americanbankingnews.comMartine A. Rothblatt Sells 3,600 Shares of United Therapeutics Co. (NASDAQ:UTHR) StockMay 4, 2024 | americanbankingnews.comUnited Therapeutics (NASDAQ:UTHR) Sets New 12-Month High Following Analyst UpgradeMay 2, 2024 | markets.businessinsider.comBuy Rating on United Therapeutics: Strong Market Position and Growth Potential Despite New CompetitorsMay 2, 2024 | finance.yahoo.comUnited Therapeutics Corp (UTHR) Q1 2024 Earnings Call Transcript Highlights: Record Revenue and ...May 2, 2024 | gurufocus.comQ1 2024 United Therapeutics Corp Earnings Call TranscriptMay 1, 2024 | msn.comLung Disease-Focused United Therapeutics Says It Is A Compelling Investment OpportunityMay 1, 2024 | msn.comUTHR Stock Earnings: United Therapeutics Beats EPS, Beats Revenue for Q1 2024May 1, 2024 | sfgate.comUnited Therapeutics: Q1 Earnings SnapshotMay 1, 2024 | finance.yahoo.comUnited Therapeutics Corporation Reports First Quarter 2024 Financial ResultsMay 1, 2024 | finance.yahoo.comUnited Therapeutics Surpasses Analyst Revenue Forecasts with Strong Q1 2024 PerformanceApril 30, 2024 | americanbankingnews.comUnited Therapeutics Co. (NASDAQ:UTHR) CEO Martine A. Rothblatt Sells 3,600 SharesApril 26, 2024 | finance.yahoo.comCORRECTING and REPLACING PHOTO United Therapeutics Announces World’s First Successful Xenothymokidney TransplantSee More Headlines Receive UTHR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for United Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/01/2024Today5/06/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:UTHR CUSIP91307C10 CIK1082554 Webwww.unither.com Phone(301) 608-9292Fax301-608-9291Employees1,168Year Founded1996Price Target and Rating Average Stock Price Target$308.78 High Stock Price Target$400.00 Low Stock Price Target$240.00 Potential Upside/Downside+18.7%Consensus RatingModerate Buy Rating Score (0-4)2.90 Research Coverage10 Analysts Profitability EPS (Most Recent Fiscal Year)$21.15 Trailing P/E Ratio12.30 Forward P/E Ratio10.90 P/E GrowthN/ANet Income$984.80 million Net Margins42.05% Pretax Margin55.28% Return on Equity18.72% Return on Assets15.35% Debt Debt-to-Equity Ratio0.04 Current Ratio3.77 Quick Ratio3.64 Sales & Book Value Annual Sales$2.33 billion Price / Sales4.96 Cash Flow$21.90 per share Price / Cash Flow11.88 Book Value$127.35 per share Price / Book2.04Miscellaneous Outstanding Shares44,370,000Free Float38,820,000Market Cap$11.55 billion OptionableOptionable Beta0.54 Social Links 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Martine A. Rothblatt J.D. (Age 69)M.B.A., Ph.D., Founder, Chairman & CEO Comp: $5.32MMr. Michael I. Benkowitz (Age 52)President & COO Comp: $2.83MMr. James C. Edgemond (Age 56)CFO & Treasurer Comp: $2.01MMr. Paul A. Mahon J.D. (Age 60)Executive VP, General Counsel & Corporate Secretary Comp: $2.31MMr. Dewey Steadman C.F.A.Head of Investor RelationsMs. Holly HobsonAssociate Vice President of Human ResourcesKevin T. GraySenior Vice President of Strategic Operations & LogisticsMr. Patrick Poisson (Age 56)Executive VP of Technical Operations Dr. Leigh PetersonExecutive Vice President of Product Development & XenotransplantationMr. Gil GoldenSenior VP & Chief Medical OfficerMore ExecutivesKey CompetitorsBioMarin PharmaceuticalNASDAQ:BMRNReata PharmaceuticalsNASDAQ:RETAIonis PharmaceuticalsNASDAQ:IONSAlkermesNASDAQ:ALKSMadrigal PharmaceuticalsNASDAQ:MDGLView All CompetitorsInsiders & InstitutionsTexas Permanent School Fund CorpBought 586 shares on 5/6/2024Ownership: 0.093%John G Ullman & Associates Inc.Sold 1,380 shares on 5/6/2024Ownership: 0.017%Mediolanum International Funds LtdBought 5,175 shares on 5/3/2024Ownership: 0.012%TFB Advisors LLCBought 896 shares on 5/3/2024Ownership: 0.004%Central Pacific Bank Trust DivisionBought 575 shares on 5/3/2024Ownership: 0.001%View All Insider TransactionsView All Institutional Transactions UTHR Stock Analysis - Frequently Asked Questions Should I buy or sell United Therapeutics stock right now? 10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for United Therapeutics in the last twelve months. There are currently 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" UTHR shares. View UTHR analyst ratings or view top-rated stocks. What is United Therapeutics' stock price target for 2024? 10 Wall Street research analysts have issued 12 month price objectives for United Therapeutics' stock. Their UTHR share price targets range from $240.00 to $400.00. On average, they predict the company's share price to reach $308.78 in the next year. This suggests a possible upside of 18.5% from the stock's current price. View analysts price targets for UTHR or view top-rated stocks among Wall Street analysts. How have UTHR shares performed in 2024? United Therapeutics' stock was trading at $219.89 on January 1st, 2024. Since then, UTHR shares have increased by 18.5% and is now trading at $260.51. View the best growth stocks for 2024 here. Are investors shorting United Therapeutics? United Therapeutics saw a increase in short interest during the month of March. As of March 31st, there was short interest totaling 4,890,000 shares, an increase of 154.7% from the March 15th total of 1,920,000 shares. Based on an average trading volume of 431,700 shares, the days-to-cover ratio is presently 11.3 days. Currently, 11.3% of the company's shares are sold short. View United Therapeutics' Short Interest. When is United Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our UTHR earnings forecast. How were United Therapeutics' earnings last quarter? United Therapeutics Co. (NASDAQ:UTHR) posted its earnings results on Wednesday, May, 1st. The biotechnology company reported $6.17 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.63 by $0.54. The biotechnology company earned $677.70 million during the quarter, compared to analysts' expectations of $620.31 million. United Therapeutics had a net margin of 42.05% and a trailing twelve-month return on equity of 18.72%. The company's quarterly revenue was up 33.7% compared to the same quarter last year. During the same period in the prior year, the business earned $4.86 earnings per share. What ETFs hold United Therapeutics' stock? ETFs with the largest weight of United Therapeutics (NASDAQ:UTHR) stock in their portfolio include Subversive Mental Health ETF (SANE), Invesco Pharmaceuticals ETF (PJP), First Trust NYSE Arca Biotechnology Index Fund (FBT), First Trust Nasdaq Pharmaceuticals ETF (FTXH), Invesco Biotechnology & Genome ETF (PBE), Formidable Fortress ETF (KONG), Inspire Faithward Mid Cap Momentum ETF (GLRY) and First Trust Health Care AlphaDEX Fund (FXH). What is Martine A. Rothblatt's approval rating as United Therapeutics' CEO? 64 employees have rated United Therapeutics Chief Executive Officer Martine A. Rothblatt on Glassdoor.com. Martine A. Rothblatt has an approval rating of 88% among the company's employees. What other stocks do shareholders of United Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other United Therapeutics investors own include Gilead Sciences (GILD), NVIDIA (NVDA), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), General Electric (GE), Johnson & Johnson (JNJ), Skyworks Solutions (SWKS), Allergan (AGN) and Pfizer (PFE). Who are United Therapeutics' major shareholders? United Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Nordea Investment Management AB (0.68%), Allspring Global Investments Holdings LLC (0.39%), Allspring Global Investments Holdings LLC (0.39%), Principal Financial Group Inc. (0.39%), Retirement Systems of Alabama (0.31%) and Polaris Capital Management LLC (0.28%). Insiders that own company stock include Christopher Causey, Christopher Patusky, Judy D Olian, Louis W Sullivan, Martine A Rothblatt, Nilda Mesa, Paul A Mahon, Paul A Mahon and Raymond Dwek. View institutional ownership trends. How do I buy shares of United Therapeutics? Shares of UTHR stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:UTHR) was last updated on 5/6/2024 by MarketBeat.com Staff From Our PartnersThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldCould Your Accounts Be Frozen?Allegiance GoldThe asset beating inflation by 4xColonial MetalsHe Is Giving Away BitcoinCrypto Swap ProfitsMissed NVDA? Buy this AI stock NOWChaikin AnalyticsElon to Transform U.S. Economy? Porter & CompanyAI “wealth window” is closing June 25thParadigm PressGold Set to EXPLODE!Gold Safe Exchange Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding United Therapeutics Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.